$WST (West Pharmaceutical Services, Inc.)

$WST {{ '2016-04-25T18:23:08+0000' | timeago}} • Announcement

$WST said it announced a strategic investment in NanoPass Technologies Ltd. This investment will provide West with access to NanoPass' knowledge and expertise in the growing area of intradermal drug delivery and future collaboration opportunities to bring new products to market.

$PG {{ '2018-01-23T20:57:54+0000' | timeago}} • Webcast

$PG plans to continue to keep bottom-line growing and to be growing margins through productivity which will both provide fuel for reinvestment and for margin improvement. $PG really doesn't view pricing and promotion as high in terms of its options to grow business. $PG is going to be continuing to invest in business to drive margins.

$PG {{ '2018-01-23T20:52:41+0000' | timeago}} • Webcast

$PG said it will continue its strong track record of cash returned to shareholders. $PG expects to pay nearly $7.5Bil in dividends this year. $PG is lifting FY18 share repurchase outlook from $4-7Bil to $6-8Bil, reflecting strong operating cash flow, continued working capital progress, and the cash benefit enabled by the Tax Act.

$PG {{ '2018-01-23T20:49:54+0000' | timeago}} • Webcast

$PG had already reduced number of agencies nearly 60% from 6,000 to 2,500, saved $750MM in agency and production costs, and improved cash flow by over $400MM additional through 75 day payment terms. In next phase, $PG expects to save another $400MM reducing number of agencies by another 50% and implementing new advertising and media agency models.

$PG {{ '2018-01-23T20:48:49+0000' | timeago}} • Webcast

$PG's core gross margin for 2Q18 declined 80 basis points versus year ago. 150 basis points of productivity savings were more than offset by headwinds of 90 points from higher commodity costs, 70 basis points of mixed impact, 50 basis points from pricing primarily Gillette, and 40 basis points of reinvestment in product and packaging innovation.

$PG {{ '2018-01-23T20:48:35+0000' | timeago}} • Webcast

$PG said commodity prices have continued to move higher as the year has progressed approaching a $350MM after-tax impact versus year ago for FY18. $PG had expected to see higher pulp costs going into the year. These costs have continued to increase beyond initial forecast ranges with strong demand and some recent supply disruption.

$PG {{ '2018-01-23T13:59:12+0000' | timeago}} • Announcement

$PG lifted FY18 core EPS growth outlook to 5-8% from 5-7% versus FY17 core EPS of $3.92. This is to reflect the potential benefit from the Tax Act. GAAP EPS are expected to decrease 30-32% versus FY17 GAAP EPS of $5.59, which included the significant benefit from the Beauty Brands transaction that was completed in October 2016.

$PG {{ '2018-01-23T13:58:56+0000' | timeago}} • Announcement

$PG maintained its organic sales growth estimate of 2-3% for FY18. The company estimates all-in sales growth of about 3% for FY18, which includes a neutral to half-a-percentage-point benefit to sales growth from the combined impacts of acquisitions and divestitures and foreign exchange.

$PG {{ '2018-01-23T13:58:44+0000' | timeago}} • Announcement

$PG's net sales for 2Q18 rose 3% year-over-year. This includes a 1% positive impact from foreign exchange. Organic sales and volume both increased 2%. A 1% positive mix impact from the disproportionate growth of higher priced categories, Skin & Personal Care and Personal Health Care, was offset by a negative pricing impact of 1%.

$PG {{ '2018-01-23T13:58:27+0000' | timeago}} • Announcement

$PG reported a 68% drop in 2Q18 earnings due to the Beauty Brands divestiture gain in the base period and the latest quarter net income tax charge related to the recent U.S. Tax Cuts and Jobs Act. Net income fell to $2.5Bil or $0.93 per share from $7.88Bil or $2.88 per share last year. Net sales rose 3% to $17.4Bil. Core EPS increased 10% to $1.19.

$PG {{ '2018-01-23T13:50:51+0000' | timeago}} • Infographic

$PG Procter & Gamble Co. Earnings AlphaGraphic: Q2 2018 Highlights

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$WRK {{ '2018-01-17T18:04:33+0000' | timeago}} • Announcement

$WRK has named James Armstrong as Vice President, Investor Relations. Most recently, Armstrong covered the paper, packaging and building materials industry through his own investment research firm. Prior to this, he was Vice President and Chief Technology Officer of Vertical Research Partners.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$HOLX {{ '2018-01-16T13:05:50+0000' | timeago}} • Announcement

$HOLX said its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for in vitro diagnostic. The Aptima HIV-1 Quant Dx assay is the first HIV-1 viral load assay with a dual claim for both diagnosis and treatment monitoring.

$HOLX {{ '2018-01-11T21:23:15+0000' | timeago}} • Announcement

Medical technology company $HOLX has elected Namal Nawana to its board of directors, effective immediately. Nawana was formerly the CEO of Alere, Inc. Prior to that, he served Johnson & Johnson in various leadership roles, including Worldwide President of DePuy Synthes Spine.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$MOS {{ '2018-01-09T12:20:12+0000' | timeago}} • Announcement

$MOS has completed the previously announced acquisition of Vale Fertilizantes from Vale S.A. Pursuant to the agreement, Luciano Siani Pires has been elected to Mosaic’s BoD. Pires has been Vale’s CFO since 2012.

$HOLX {{ '2018-01-08T13:10:32+0000' | timeago}} • Announcement

Medical technology company $HOLX said it is currently looking for net revenues of about $791MM for the first quarter of 2018, higher than $775MM-$790MM the company had estimated earlier. The latest guidance represents an 8% YoY growth, reflecting the effect of divestiture of Hologic’s blood screening business and acquisition of Cynosure.

$WRK {{ '2018-01-08T12:11:46+0000' | timeago}} • Announcement

$WRK completed the previously announced acquisition of Plymouth Packaging, Inc., a corrugated packaging company. This latest acquisition represents $WRK's entry into the corrugated packaging market. Financial details of the deal remained undisclosed.

$HOLX {{ '2018-01-03T13:10:03+0000' | timeago}} • Announcement

$HOLX said the MyoSure MANUAL device, which was designed to simplify tissue removal procedures regardless of setting, has received CE mark in Europe. The MyoSure MANUAL device joins the MyoSure suite of gynecologic surgical products that offer simple and effective solutions to resect and remove tissue.

Recent Transcripts

PG (The Procter & Gamble Company)
Tuesday, January 23 2018 - 1:30pm
URG (UR-Energy Inc.)
Friday, January 19 2018 - 4:00pm
RAVN (Raven Industries Inc.)
Tuesday, November 21 2017 - 3:00pm
MDWD (MediWound Ltd.)
Thursday, November 16 2017 - 1:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
ASH (Ashland Inc.)
Tuesday, November 7 2017 - 2:00pm
VGZ (Vista Gold Corp.)
Thursday, November 2 2017 - 8:30pm
MLM (Martin Marietta Materials, Inc.)
Thursday, November 2 2017 - 3:00pm
WRK (WestRock Company)
Thursday, November 2 2017 - 12:30pm
CLX (The Clorox Company)
Wednesday, November 1 2017 - 5:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MOS (The Mosaic Company)
Tuesday, October 31 2017 - 1:00pm
IPHS (Innophos Holdings Inc)
Tuesday, October 31 2017 - 1:00pm
RVLT (Revolution Lighting Technologies, Inc.)
Thursday, October 26 2017 - 3:00pm
WST (West Pharmaceutical Services, Inc.)
Thursday, October 26 2017 - 1:00pm
PKG (Packaging Corporation of America)
Thursday, October 26 2017 - 1:00pm
USNA (USANA Health Sciences Inc.)
Wednesday, October 25 2017 - 3:00pm
SLGN (Silgan Holdings Inc.)
Wednesday, October 25 2017 - 3:00pm
IP (International Paper Company)
Wednesday, October 25 2017 - 2:00pm

AlphaGraphics you may like